

21st February 2022

RE: ORENCIA STOCK HYPERCARE PLAN (OSHP)

Dear Pharmacist,

Orencia (abatacept) subcutaneous presentations are experiencing low stock and intermittent supply risk globally. This shortage is due to a combination of manufacturing capacity constraints, supplier component challenges and shipment delays.

Due to the limited available stock of both Orencia subcutaneous presentations, the Australian Rheumatology Association (ARA) have recommended that this stock be conserved for patients who meet certain eligibility criteria. To ensure that eligible patients can access the available stock, BMS have developed the Orencia Stock Hypercare Plan (OSHP) which will be effective from the 21st of February 2022.

For the OSHP ordering process please refer to the next page.

BMS/DHL will notify you via email/iStore when the OSHP is no longer required. Should you have additional patients who wish to order Orencia during this time, we recommend that the patient consults with their physician to discuss eligibility for supply.

BMS Australia is making every effort to resolve the situation as early as possible. We know the importance of steady and reliable supply of critical medicines for patients and remain committed to delivering this medicine to patients who need it. We will continue to work closely with the TGA, ARA and Arthritis Australia to manage the shortages with the goal of minimising the impact on patients in Australia.

For enquiries please contact:

DHL Ordering BMS Medical information
1800 077 421 1800 067 567 (select option 2)
d2mcs@dhl.com medinfo.australia@bms.com

We thank you for your support and appreciate your patience during this period of constrained supply.

Yours sincerely,

Meredith Edwards

Associate Medical Director Bristol-Myers Squibb Australia



ORENCIA STOCK HYPERCARE PLAN (OSHP) ORDERING PROCESS

Effective from Monday 21st February 2022 until further notice

1. OSHP Eligibility Form issued by physician

 Patients eligible to receive subcutaneous abatacept (Orencia) supply will receive a OSHP Eligibility Form from their physician with the physician fields completed

Patient presents to pharmacy with OSHP Eligibility Form & script OR OSHP Eligibility form is emailed to pharmacy from patient or physician

2. Pharmacist receives OSHP Eligibility Form

- · Steps required by pharmacist:
 - ☐ Check stock availability of abatacept (Orencia) subcutaneous presentations
 - Review the BMS Home Page on DHLs' iStore (direct.dhl.com)¹ OR
 - · Review the daily stock status update email from DHL
 - ☐ Determine if patient's preferred subcutaneous presentation² is available:
 - Yes → proceed to ordering
 - No → discuss the availability of the alternative presentation with the patient, consider substitution under the TGA Serious Scarcity Substitution Instrument (SSSI)³ & proceed to ordering if appropriate

3. Pharmacist places abatacept (Orencia) order

- · Steps required by pharmacist:
 - ☐ Email order⁴ & OSHP Eligibility Form to DHL (<u>d2mcs@dhl.com</u>)
 - · Include 'OSHP' in the email subject line; do not include the patient's script in the email
 - Note: DHL will only be accepting emailed orders for abatacept (Orencia) subcutaneous presentations while the OSHP is in effect
 - This order will take approximately 3 to 5 days for delivery depending on the weekday & pharmacy location
 - ☐ Provide patient with details of the patient resource website 'Orencia GO' if instructions & videos on how to administer the Orencia pre-filled syringe or the Orencia autoinjector (ClickJect) are required
 - Link: www.bms.com/au/gated/OrenciaGO.html (Password: BMSGO)
 - ☐ Instruct patient to keep their OSHP Eligibility Form & to bring it with them when their next script repeat is required OR keep this form on record for use when ordering future repeats for the patient
- 1. If you are not registered for iStore please register via DHL's Landing page (direct.dhl.com)
- 2. As indicated in the OSHP Eligibility Form & script
- To support patients on Orencia Subcutaneous formulations during this period, the TGA has put in place a Serious Scarcity Substitution Instrument
 (SSSI). This SSSI declares Orencia (abatacept) pre-filled syringe and the Orencia (abatacept) 125mg/mL subcutaneous autoinjector (ClickJect) as scarce
 and substitutable medicines, making the medicines effectively interchangeable at the pharmacy level. For more details, please refer to the TGA
 website: https://www.tga.gov.au/serious-scarcity-substitution-instruments-sssis.
- 4. Ensure to include the following details in the order: Pharmacy name; Pharmacy Account no.; Product Description; SKU no.; Quantity. Note: Only 1 unit per patient will be accepted per order, patients are expected to receive 1 repeat per month.